Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with a private placement
Mandate

Vinge advises Cinclus Pharma in connection with a private placement

May 20, 2022 Intellectual Property Capital Markets and Public M&A Corporate Tax

Vinge has advised the biopharmaceutical development company Cinclus Pharma in connection with a private placement of approximately SEK 240 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of linaprazan glurate, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD), accelerate the Company’s commercialization strategy and broaden the shareholder base.

Vinge’s team consisted primarily of Dain Hård Nevonen, Amanda Knutsson, Stojan Arnerstål, Maria Schultzberg and Anna Svensson.

Related

Vinge advises Smart Eye on acquisition of Sightic Analytics

 Smart Eye has entered into an agreement to acquire all shares in Sightic Analytics for a fixed purchase price of SEK 60.5 million, to be paid with newly issued shares in Smart Eye, and an additional purchase price of up to SEK 50 million, conditional upon certain financial and operational targets being met.
February 24, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB.
February 22, 2026

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

 Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026